TELO - NASDAQ
Telomir Pharmaceuticals, Inc. Common Stock
$1.48
+0.0000%Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
At a Glance
Live Snapshottelo
Total Assets
Last Annual Value
7.34M
3-Year CAGR
432%
5-Year CAGR
166%
10-Year CAGR
63%
Telomir Pharmaceuticals, Inc. Common Stock Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | 7.34M | 15.4% | 166.1% | N/A | |
 CEL-SCI Corporation AMEX:CVM | 26.99M | -4.0% | -18.7% | 8.8% | |
 Equillium, Inc. NASDAQ:EQ | 31.89M | -14.2% | -17.9% | N/A | |
 INmune Bio, Inc. NASDAQ:INMB | 39.56M | -11.5% | -16.9% | 56.4% | |
 Coeptis Therapeutics, Inc. NASDAQ:COEP | 19.84M | 35.0% | 24.0% | N/A | |
 Century Therapeutics, Inc. NASDAQ:IPSC | 223.70M | -14.7% | -12.5% | N/A | |
 Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 129.72M | -2.1% | 4.0% | N/A | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 144.66M | -13.8% | -6.8% | 3.2% | |
 Estrella Immunopharma, Inc. NASDAQ:ESLA | 3.18M | -10.7% | -8.4% | N/A | |
 OS Therapies Incorporated NYSE:OSTX | 5.54M | 90.7% | 76.2% | N/A | |
 Senti Biosciences, Inc. NASDAQ:SNTI | 97.84M | -6.4% | 0.2% | N/A |
Telomir Pharmaceuticals, Inc. Common Stock Fair Value Envelope
Related Guides
Continue your TELO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.